...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods
【24h】

Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods

机译:通过CLSI和EUCAST肉汤微稀释法测试的E1210和比较剂对通过分子鉴定方法鉴定的镰刀菌和镰孢菌种的活性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Fusarium (n = 67) and Scedosporium (n = 63) clinical isolates were tested by two reference broth microdilution (BMD) methods against a novel broad-spectrum (active against both yeasts and molds) antifungal, E1210, and comparator agents. E1210 inhibits the inositol acylation step in glycophosphatidylinositol (GPI) biosynthesis, resulting in defects in fungal cell wall biosynthesis. Five species complex organisms/species of Fusarium (4 isolates unspeciated) and 28 Scedosporium apiospermum, 7 Scedosporium aurantiacum, and 28 Scedosporium prolificans species were identified by molecular techniques. Comparator antifungal agents included anidulafungin, caspofungin, itraconazole, posaconazole, voriconazole, and amphotericin B. E1210 was highly active against all of the tested isolates, with minimum effective concentration (MEC)/MIC 90 values (μg/ml) for E1210, anidulafungin, caspofungin, itraconazole, posaconazole, voriconazole, and amphotericin B, respectively, for Fusarium of 0.12, 16, 16, 8, 8, 8, and 4 μg/ml. E1210 was very potent against the Scedosporium spp. tested. The E1210 MEC 90 was 0.12 μg/ml for S. apiospermum, but 1 to 8 μg/ml for other tested agents. Against S. aurantiacum, the MEC 50 for E1210 was 0.06 μg/ml versus 0.5 to 8 μg/ml for the comparators. Against S. prolificans, the MEC 90 for E1210 was only 0.12 μg/ml, compared to 4 μg/ml for amphotericin B and 8 μg/ml for itraconazole, posaconazole, and voriconazole. Both CLSI and EUCAST methods were highly concordant for E1210 and all comparator agents. The essential agreement (EA; ±2 doubling dilutions) was 93% for all comparisons, with the exception of posaconazole and F. oxysporum species complex (SC) (60%), posaconazole and S. aurantiacum (85.7%), and voriconazole and S. aurantiacum (85.7%). In conclusion, E1210 exhibited very potent and broad-spectrum antifungal activity against azole-and amphotericin B-resistant strains of Fusarium spp. and Scedosporium spp. Furthermore, in vitro susceptibility testing of E1210 against isolates of Fusarium and Scedosporium may be accomplished using either of the CLSI or EUCAST BMD methods, each producing very similar results.
机译:通过两种参考肉汤微稀释(BMD)方法对新型广谱抗真菌剂,E1210和比较剂进行了镰刀菌(n = 67)和镰孢菌(n = 63)临床分离株的测试。 E1210抑制糖磷脂酰肌醇(GPI)生物合成中的肌醇酰化步骤,导致真菌细胞壁生物合成中的缺陷。通过分子技术鉴定了镰刀菌的5种复杂生物体/物种(4种未鉴定的菌株)和28种臭皮孢子菌,紫红色的7种孢子菌和28种多产的孢子菌。比较剂抗真菌药包括阿尼芬净,卡泊芬净,伊曲康唑,泊沙康唑,伏立康唑和两性霉素B.E1210对所有测试的分离物均具有很高的活性,E1210,阿尼芬净,卡泊芬净,伊曲康唑,泊沙康唑,伏立康唑和两性霉素B的镰刀菌分别为0.12,> 16,> 16,> 8,> 8、8和4μg/ ml。 E1210对Scedosporium spp非常有效。经过测试。 E1210 MEC 90对于无子链霉菌为0.12μg/ ml,而对于其他受试药物,为1至> 8μg/ ml。对于S. aurantiacum,E1210的MEC 50为0.06μg/ ml,而比较例为0.5至> 8μg/ ml。对抗S. prolificans,E1210的MEC 90仅为0.12μg/ ml,而两性霉素B的MEC 90> 4μg/ ml,伊曲康唑,泊沙康唑和伏立康唑的MEC 90则大于8μg/ ml。 CLSI和EUCAST方法对于E1210和所有比较器代理都是高度一致的。所有比较的基本一致性(EA;±2倍稀释度)> 93%,但泊沙康唑和尖孢镰刀菌种复合物(SC)(60%),泊沙康唑和a链霉菌(85.7%)和伏立康唑除外和S. aurantiacum(85.7%)。总之,E1210对镰刀菌属的耐唑和两性霉素B的菌株表现出非常有效的广谱抗真菌活性。和Scedosporium spp。此外,可以使用CLSI或EUCAST BMD方法中的任何一种完成E1210对镰孢镰刀菌和Scedosporium分离物的体外药敏试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号